#BIO22: Fire­side Chat with John Car­roll & Stéphane Ban­cel; 'No­body needs the type of wealth that we have'

2 months ago

#BIO22: Man­ag­ing a biotech in tur­bu­lent times. 'There's a per­fect shit­show out there'

2 months ago

Scoop: A small gene ther­a­py biotech, flush with ex-Sarep­ta and blue­bird lead­ers, guts CMC

2 months ago
People
Cell/Gene Tx

Scoop: Roche scraps one of two schiz­o­phre­nia PhII tri­als af­ter fail­ing the pri­ma­ry end­point

2 months ago
R&D
Pharma

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

2 months ago
Pharma
In Focus

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

3 months ago
R&D

Con­gress lays out its de­mands for FDA in 2023 — on every­thing from ma­chine learn­ing to im­munother­a­pies

3 months ago
FDA+

FDA+ roundup: Spring reg­u­la­to­ry agen­da looks to fin­ish off Cures im­ple­men­ta­tion; GAO digs in­to med­ical coun­ter­mea­sures

3 months ago
FDA+

UP­DAT­ED: Gala­pa­gos CEO Paul Stof­fels bets €225M on a new CAR-T strat­e­gy for the long suf­fer­ing biotech

3 months ago
Deals

15 lead­ers giv­ing voice and vis­i­bil­i­ty to the LGBTQ com­mu­ni­ty in bio­phar­ma

3 months ago
People
Special

No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot gene edit­ing field

3 months ago
Deals

In­ter­view with the Broad In­sti­tute's David Liu: Is this the year base edit­ing makes its mark?

3 months ago
Cell/Gene Tx

#BIO22: By the Num­bers: Af­ter the mu­sic died, you can see some en­cour­ag­ing signs on the M&A and li­cens­ing fronts. But where's the big buy-in?

3 months ago
Deals

Ex­clu­sive: GV’s David Schenkein turns to a fa­mil­iar face at No­var­tis for his lat­est re­cruit as en­tre­pre­neur-in-res­i­dence

3 months ago
People

#AS­CO22: Min­gling face-to-face stole the spot­light in re­union with '50,000 of your clos­est friend­s'

3 months ago
People

#AS­CO22: A small Chi­na biotech play­er makes its de­but at AS­CO with promis­ing da­ta on its GPRC5D mul­ti­ple myelo­ma drug

3 months ago
Bioregnum
China

FDA's Pe­ter Marks lays out plans to sup­port gene ther­a­pies for ul­tra-rare dis­eases

3 months ago
Cell/Gene Tx
FDA+

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

4 months ago
R&D
In Focus

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

4 months ago
People
Discovery

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

4 months ago
Deals
R&D

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

4 months ago
People
AI

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

4 months ago
R&D

Still-in-stealth biotech part­ners with Sloan Ket­ter­ing sci­en­tists to make per­son­al­ized can­cer ther­a­py more ‘pub­lic’

4 months ago
Discovery
Cell/Gene Tx

As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

4 months ago
Deals
Bioregnum
First page Previous page 123456 Next page Last page